Means-Plus-Function and Antibody Patent Claims: Preparing, Defending, and Enforcing MPF Claims Firm NewsMichelle E. O’BrienPh.D.Thomas L. Irving Means-Plus-Function and Antibody Patent Claims: Preparing, Defending, and Enforcing MPF Claims
Federal Circuit Refuses Patentee’s Request to Revive Term-Adjusted Patent Claims Held Unpatentable for Obviousness-Type Double Patenting Court DecisionsCourt OpinionMichelle E. O’Brienobviousness-type double patentingodpodtpPatentpatent term adjustmentptaThomas L. Irving Federal Circuit Refuses Patentee’s Request to Revive Term-Adjusted Patent Claims Held Unpatentable for Obviousness-Type Double Patenting
Prosecution and Specification Statements: Implications for Patent Claim Construction in Parent and Sibling Applications and PTAB and District Court/Federal Circuit Litigation Firm NewsMichelle E. O’BrienThomas L. Irving Prosecution and Specification Statements: Implications for Patent Claim Construction in Parent and Sibling Applications and PTAB and District Court/Federal Circuit Litigation
Proving and Avoiding Inequitable Conduct and Unclean Hands in Patent Prosecution and Litigation Firm NewsThomas L. Irving Proving and Avoiding Inequitable Conduct and Unclean Hands in Patent Prosecution and Litigation
Federal Circuit Takes Rare Step of Sending Issue of Obviousness Back to PTAB in Ex Parte Appeal Court CasesMichelle E. O’BrienPatentScott B. AmankwatiaThomas L. Irving Federal Circuit Takes Rare Step of Sending Issue of Obviousness Back to PTAB in Ex Parte Appeal
ChatGPT and NLP in Patent Prosecution Benjamin B. MazaheryFirm News ChatGPT and NLP in Patent Prosecution
Inducement in a Pharmaceutical, Post-Launch Non-Hatch-Waxman World: Evaluating the Effect of a Skinny Label, Implications of GSK v. Teva Firm NewsMichelle E. O’BrienThomas L. Irving Inducement in a Pharmaceutical, Post-Launch Non-Hatch-Waxman World: Evaluating the Effect of a Skinny Label, Implications of GSK v. Teva
U.S. Supreme Court Finds Against Amgen: The More You Claim the More You Must Enable; The Result of Being too Obscure, Loose, and Imperfect Court CasesCourt DecisionsMichelle E. O’BrienPatentThomas L. Irving U.S. Supreme Court Finds Against Amgen: The More You Claim the More You Must Enable; The Result of Being too Obscure, Loose, and Imperfect
U.S. Supreme Court Denies Teva’s Petition for Certiorari in Skinny Label Case Court DecisionsMichelle E. O’BrienThomas L. Irving U.S. Supreme Court Denies Teva’s Petition for Certiorari in Skinny Label Case